# Nanobiotix

Source: https://onco.cc/companies/nanobiotix/  
OnCo record `nanobiotix` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Nanobiotix is the Paris nanomedicine company behind NBTXR3, hafnium oxide nanoparticles injected into a tumour to make radiotherapy deposit more energy inside it.

## Summary

Founded in 2003 and listed on Euronext Paris and Nasdaq, Nanobiotix built its business on the physics of radioenhancement: high atomic number nanoparticles that absorb X-rays and amplify the dose within the tumour. Its lead product NBTXR3 received a European CE mark for soft-tissue sarcoma in 2019 and is in the NANORAY-312 phase 3 trial in head and neck cancer, licensed to Johnson and Johnson in 2023.

## Fields

- Kind: Company
- Last checked: 2026-09-16
- Tags: radiation-wave3; radiation
- HQ: Paris, France
- Type: biotech
- Website: https://www.nanobiotix.com

## Sources

- Official website: https://www.nanobiotix.com

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/)
- technologies: [Radiosensitisers](https://onco.cc/technologies/radiosensitisers/)
- drugs: [NBTXR3 (hafnium oxide nanoparticles)](https://onco.cc/drugs/nbtxr3/)

---
JSON: https://onco.cc/api/v1/entities/nanobiotix.json